News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Ian Flinn, MD, PhD, Sarah Cannon Research Institute

Articles by Ian Flinn, MD, PhD, Sarah Cannon Research Institute

DLBCL: Circumstances for Deviating Away From R-CHOP

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

January 29th 2021

Trending on OncLive

Domvanalimab/Zimberelimab Plus Chemotherapy Fails to Improve OS in HER2-Negative Gastroesophageal Adenocarcinoma

Extended FOLFOX, Atezolizumab Duration Linked With Improved DFS in Stage III dMMR Colon Cancer

Bexobrutideg Could Pave the Way for BTK Degraders in R/R Chronic Lymphocytic Leukemia

AI Finds New Applications in Oncologic Surgery, Drug and Biomarker Screening, and Clinical Trial Design

ESR1 Mutations Steer the Oral SERD Story in Breast Cancer: With Sara Nunnery, MD, MSCI; and MinhTri Nguyen, MD